Amphastar Pharmaceuticals (AMPH) Jefferies London Healthcare Conference 2024 summary

Strategic execution and recent performance

• Successfully launched generic glucagon, acquired Baqsimi, and expanded into proprietary prescription products, remaining the sole generic glucagon in the U.S. market.

• Manufacturing capacity increased by 10% annually over three years, with a long-term plan to quadruple capacity at the main facility.

• Addressed production bottlenecks, aiding in alleviating FDA drug shortages without significant new capital expenditure.

• Top six products contribute nearly 75% of revenues, with glucagon sales nearly doubling in recent years due to capacity expansion and market shortages.

• Primatene Mist achieved $100 million in 2024 sales, driven by volume growth and marketing, with no price increase in 2024; remains the only FDA-approved OTC asthma inhaler.

Product and market dynamics

• Glucagon expected to decline as market shifts to ready-to-use products like Baqsimi, but pipeline products AMP-002 and AMP-007 offer significant growth opportunities.

• Baqsimi sales are 80% U.S.-based, with peak sales estimate maintained at $250–$275 million; dedicated U.S. sales team established and further expansion planned for 2025.

• 3Q Baqsimi sales benefited from seasonality but were constrained in Europe due to supply chain issues, now largely resolved.

• Epinephrine prefilled syringes benefited from ongoing shortages, while multi-dose vials face competition and price pressure; Canadian exports supplement demand.

• Lidocaine and phytonadione performance fluctuates with market dynamics, supply, and competition, with lidocaine benefiting from product diversity and stable segments.

Pipeline and future outlook

• Four key pipeline products (AMP-002, AMP-015, AMP-018, AMP-007) targeted for 2025 launches, with AMP-002 and AMP-007 seen as the largest opportunities.

• AMP-002 awaiting FDA action; AMP-015 received a minor CRL, with resubmission planned by year-end and potential approval in 2025.

• Strategic focus shifting toward proprietary and biosimilar products, projecting these to comprise 85% of the pipeline by 2025, up from 37% in 2021.

• R&D investment remains a priority, with $345 million self-funded over five years, supporting a diverse and scalable pipeline.

• 2025 projected as a normalized year post-Lilly transition, with growth dependent on new approvals; each additional approval expected to be accretive to margins.